- Home
- TRIP vs IDYA Comparison
TRIP vs IDYA Comparison
Compare TRIP & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIP
- IDYA
- Stock Information
- Founded
- TRIP 2000
- IDYA 2015
- Country
- TRIP United States
- IDYA United States
- Employees
- TRIP N/A
- IDYA N/A
- Industry
- TRIP Computer Software: Programming Data Processing
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- TRIP Technology
- IDYA Health Care
- Exchange
- TRIP Nasdaq
- IDYA Nasdaq
- Market Cap
- TRIP 2.1B
- IDYA 2.0B
- IPO Year
- TRIP 2011
- IDYA 2019
- Fundamental
- Price
- TRIP $15.11
- IDYA $21.85
- Analyst Decision
- TRIP Hold
- IDYA Strong Buy
- Analyst Count
- TRIP 14
- IDYA 13
- Target Price
- TRIP $17.79
- IDYA $53.67
- AVG Volume (30 Days)
- TRIP 2.6M
- IDYA 972.2K
- Earning Date
- TRIP 02-20-2025
- IDYA 02-13-2025
- Dividend Yield
- TRIP N/A
- IDYA N/A
- EPS Growth
- TRIP N/A
- IDYA N/A
- EPS
- TRIP 0.04
- IDYA N/A
- Revenue
- TRIP $1,835,000,000.00
- IDYA $7,000,000.00
- Revenue This Year
- TRIP $7.47
- IDYA $111.81
- Revenue Next Year
- TRIP $7.76
- IDYA $240.55
- P/E Ratio
- TRIP $423.67
- IDYA N/A
- Revenue Growth
- TRIP 2.63
- IDYA N/A
- 52 Week Low
- TRIP $12.93
- IDYA $19.96
- 52 Week High
- TRIP $28.76
- IDYA $47.72
- Technical
- Relative Strength Index (RSI)
- TRIP 33.00
- IDYA 43.52
- Support Level
- TRIP $17.13
- IDYA $19.96
- Resistance Level
- TRIP $18.09
- IDYA $21.65
- Average True Range (ATR)
- TRIP 0.72
- IDYA 1.09
- MACD
- TRIP -0.33
- IDYA -0.07
- Stochastic Oscillator
- TRIP 5.08
- IDYA 33.57
About TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2023, 58% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 41% of sales in 2023, and TheFork, its dining brand, represented 9% of revenue (about 8% of sales were intersegment, which are eliminated from consolidated revenue).
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.